×

Uh-oh, it looks like your Internet Explorer is out of date.

For a better shopping experience, please upgrade now.

New Therapeutic Agents in Thrombosis and Thrombolysis
     

New Therapeutic Agents in Thrombosis and Thrombolysis

by Arthur Sasahara (Editor), Joseph Loscalzo (Editor)
 
Presents new chapters discussing the latest research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase.

Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies to

  • target conventional and recently characterized pathways of
  • Overview

    Presents new chapters discussing the latest research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase.

    Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies to

  • target conventional and recently characterized pathways of hemostasis
  • minimize the prothrombotic function of activated platelets
  • assess the biochemical and pharmacological effects of antithrombotic agents
    and discusses
  • the use of animal models for determination of antithrombotic drug efficacy
  • antithrombotic therapy as a key component of cardiovascular disease management
  • the management of thromboembolic events in children and pregnant women
    Supplemented with more than 2000 contemporary references, New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.
  • Editorial Reviews

    Doody's Review Service
    Reviewer: John F. Moran, MD (Loyola University Stritch School of Medicine)
    Description: This multiauthored entry in the Fundamental and Clinical Cardiology series is divided into four sections covering an overview, new heparins and thrombin inhibitors, new antiplatelet agents, and new thrombolytic agents.
    Purpose: It has been five years since the first edition came out. This is a rapidly advancing field, and more information has developed in the last few years that required a new understanding of hemostasis. There are many new agents targeting various steps in the hemostasis cascade.
    Audience: This book will appeal to hematologists, but it will also appeal to cardiologists who deal with these agents on a daily basis. Cardiology fellows would find much worthwhile here as well.
    Features: The book starts with a review of the clotting cascade and a critical review of clinical trial design, e.g., the lack of placebo controls, equivalences, no inferiority track, the small patient numbers in subgroups of small trials, and inconsistent end-points. The trials in low molecular weight heparin and its role in the acute coronary syndrome are reviewed, as well as those with glycoprotein IIb/IIIa inhibitors. The role of low molecular weight heparin in pregnancy is reviewed, as are new indications for low molecular weight heparin, generally (for example, transluminal coronary angioplasty, inflammatory bowel disease, sepsis, and Alzheimer's disease). The agent Argatroban is the smallest molecule in the class of thrombin inhibitors, and can penetrate and neutralize thrombin at a two-fold increase in concentration. This agent is important in heparin-induced thrombocytopenia and thrombosis, as well as in those patients who require a percutaneous intervention. Hirudin and Bivaluridin are reviewed, and a comparison with unfractionated heparin is reviewed. The new oral agents, Ximelagatrin and Pentasaccharide are important antithrombotic agents in development. The role of tissue factor pathway inhibitor in thrombosis is reviewed, with an emphasis on transluminal coronary angioplasty, cerebral vascular accidents, and gliomas. The importance of protein C and S as antithrombotics will always be important in certain areas, especially warfarin-induced skin necrosis. The interaction of protein C and S with thrombomodulin and thrombosis is well described. There are chapters on the glycoprotein IIb/IIIa receptor blockers. Over 100 pages of the book are devoted to new data on thrombolytic therapy. The epilogue summarizes the present, and points to the future use of anticoagulation.
    Assessment: When compared to the first edition, the first few chapters pf this book are nearly the same, but the rest is enhanced by new developments in this important area. The book is full of important information, and is a definite addition to the medical literature. Many of the chapters have more than 100 references to original work.
    3 Stars from Doody
    New England Journal of Medicine
    ...each section begins with an overview of the important new developments in the areas as assessed by the section editors. I enjoyed reading this book and found it a valuable source of novel information... This book will appeal to a broad spectrum of basic and clinical investigators working in the area of thrombosis, particularly those interested in drug development...
    Atherosclerosis
    ...an impressive array of expert contributors....very well referenced throughout... Chapters on tissue factor pathway inhibitor[s]...are particularly good, easily readable, very informative and extremely well referenced. ...excellent.
    Ferdinand S. Leya
    This book reviews the latest scientific knowledge and clinical data regarding new therapeutic agents in the field of thrombosis and thrombolysis. It reflects the expertise of almost 80 authors, some of them world-leading research and clinical authorities in the field of thrombosis and thrombolysis. The purpose is to review and compare the newest antithrombotic and fibrinolytic agents as well as to summarize the latest scientific and clinical concepts in hemostasis and thrombosis research. This well-written book certainly meets the authors' criteria of summarizing and clarifying a vast array of ever-changing amounts of scientific and clinical data. For a complete reading, this book will be useful for cardiologists, cardiology fellows, internists, hematologists, and neurologists with special interest in thrombotic disorders, as well as cardiovascular researchers who are actively involved in the hemostasis, thrombosis, and thrombolysis basic and clinical research. The book is modestly illustrated in black and white. Most of them consist of drawings, tables, and charts. Some of them did not reproduce well. There is a virtual lack of original photographs, and those that are present reproduced poorly. This is an excellent review book and reference source for those who have a special interest and background in the field of thrombosis and hemostasis. I would recommend it as a good new source of organized information to any medical library. This book is limited to the new therapeutic agents and the latest scientific concepts; therefore, it does not sufficiently address the broader, already well-established concepts of thrombosis and thrombolysis. As such, it is an addition and anextension of such books as Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edited by R. W. Colman et al. (J.B. Lippincott Co., 1994) or Thrombosis in Cardiovascular Disorders, edited by Valentine Fuster et al. (W.B. Saunders Co., 1992).
    Booknews
    Thirty-six contributions provide clarification of the explosive growth therapeutic agents targeted to interfere with the pathways contributing to thrombosis. The first section contains four overviews dealing with new concepts of hemostasis and thrombolysis, animal models, experimental strategies using animal models, and design issues in clinical trails. Subsequent sections discuss new heparins, thrombin inhibitors, and other new agents; new antiplatelet agents; and new thrombolytic agents. Each section begins with an overview, and each chapter includes a section on preclinical science and the results of Phase I or II clinical experience. Annotation c. by Book News, Inc., Portland, Or.

    Product Details

    ISBN-13:
    9780824707958
    Publisher:
    Taylor & Francis
    Publication date:
    10/28/2002
    Series:
    Fundamental and Clinical Cardiology Series
    Edition description:
    REV
    Pages:
    720
    Product dimensions:
    6.25(w) x 9.25(h) x 1.25(d)

    Customer Reviews

    Average Review:

    Post to your social network

         

    Most Helpful Customer Reviews

    See all customer reviews